Companies /Healthcare

Qiagen NV

NYSE: QGEN Diagnostics & Research
$49.85
▼ $0.05 (−0.09%) today
Markets open · 3:43pm ET

24/7 Wall St. View

QGEN at a Glance

Valuation
Market cap
$10.3B
P/E ratio
27.0
Dividend yield
0.70%
Profitability
Revenue (TTM)
$2.1B
Profit margin
18.2%
EPS (TTM)
$1.85
Price
52-week range
$32 – $57
24/7 target
$53.22
Street target
$49.77
Earnings
Next report
Feb 2, 2027

Headquartered in Hulsterweg 82, Venlo Fiscal year ends December NYSE: QGEN qiagen.com

About Qiagen

QIAGEN N.V. is a Netherlands-based holding company providing 'Sample to Insight' solutions that let customers extract and analyze molecular information from biological samples. Its offering spans several areas:
- **Sample technologies:** Isolate and process DNA, RNA and proteins from blood, tissue and other materials. Products include automated and manual kits; instruments such as QIAsymphony Connect, QIAsprint Connect and QIAmini; and single-cell kits and services from Parse Biosciences, acquired in late 2025.
- **Diagnostic solutions:** QuantiFERON-TB Gold Plus for latent tuberculosis testing, the QIAstat-Dx syndromic testing system, and Precision Medicine companion diagnostics.
- **PCR / nucleic acid amplification:** Includes the QIAcuity digital PCR platform, qPCR products and OEM products.
- **Genomics / NGS:** Universal NGS panels and QIAGEN Digital Insights bioinformatics, including clinical bioinformatics, IPA and Genoox.

Consumables and related revenues account for about 91% of sales. QIAGEN serves more than 500,000 customers in Life Sciences (academia, pharmaceutical R&D and industrial applications such as forensics) and Molecular Diagnostics (clinical healthcare). It employed about 5,400 people across more than 35 locations as of September 30, 2026. In October 2026, QIAGEN agreed to be acquired by the EQT XI fund through an all-cash public takeover offer of €46.50 per share, expected to close in mid-2027. Updated

QGEN Coverage

12:50pm ET
Health and Healthcare

ETF Folly: Biotech ETFs, Nothing but Confusion

Thinkstock24/7 Wall St. has always wondered about the confusing universe of biotech exchange-traded funds (ETFs). Biotech stocks can rise or fall regardless of the market direction, and the sector performed very well…

Jon C. Ogg

Frequently Asked Questions

What does Qiagen do?

QIAGEN N.V. is a Netherlands-based holding company providing 'Sample to Insight' solutions that let customers extract and analyze molecular information from biological samples. Its offering spans several areas: - **Sample technologies:** Isolate and process DNA, RNA and proteins from blood, tissue and other materials.

What is the QGEN stock price target?

24/7 Wall St.'s 12-month price target for QGEN is $53.22, rated Buy. The Wall Street consensus target is $49.77. QGEN price prediction →